Worth a Shot? Evidence-Based Approach to Prescribing LAI Antipsychotic Medications-View Presentation

Video Transcription

Video Summary

The webinar hosted by Donna Rowland, Director of the Psychiatric Mental Health Nurse Practitioner Program at the University of Texas, Austin, focused on the use of long-acting injectable (LAI) antipsychotic medications in schizophrenia treatment. Dr. Leon Raven, a board-certified psychiatrist, led the discussion, highlighting evidence-based benefits of LAIs over oral antipsychotics. Key insights included reduced mortality, decreased hospitalization, and better medication adherence with LAIs. The presentation emphasized the importance of educating patients about treatment options, especially for those with schizophrenia, encouraging early LAI usage after diagnosis. Attendees learned that LAIs ensure consistent medication levels, reducing the risk of non-adherence often seen with oral medications. Comparisons favored second-generation LAIs due to fewer side effects and better adherence. Challenges in random controlled trials versus observational studies were discussed, noting the latter often shows more realistic clinical benefits of LAIs. The Q&A addressed concerns about treatment consistency and innovations in LAI formulations. Resources, including follow-up consultation opportunities with SMI Advisor, were also offered to participants, alongside reminders about claiming professional development credits.

Keywords

long-acting injectables

schizophrenia treatment

antipsychotic medications

medication adherence

second-generation LAIs

psychiatric education

clinical benefits

Donna Rowland

Leon Raven